TATRIGBI

Welcome to the Brand page for “TATRIGBI”, which is offered here for Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, alzheimer, sepsis, and restenosis; vaccine preparations; vaccines; biological preparations in the nature of antibodies for use in the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, alzheimer, sepsis, and restenosis; antibodies sold as an ingredient of pharmaceuticals for the treatment of treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, alzheimer, sepsis, and restenosis; diagnostic preparations for medical or veterinary purposes; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, alzheimer, sepsis, and restenosis; sanitary preparations for medical use; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, alzheimer, sepsis, and restenosis;research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design services, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, alzheimer, sepsis, and restenosis; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development services in the field of antibodies;.

Its status is currently believed to be active. Its class is unavailable. “TATRIGBI” is believed to be currently owned by “MorphoSys AG”.